Pascal Soriot, chief executive officer of AstraZeneca Plc, speaks during an interview in New York, U.S., on Wednesday, June 4, 2014. Newly reported data for AstraZeneca Plc's experimental cancer treatments "gives credibility" to the drugmaker's forecast of $45 billion in annual revenue by 2023, according to Soriot. Photographer: Victor J. Blue/Bloomberg via Getty Images
Getty Images

Bloomberg Bloomberg